Published on 22/12/2025
Veterans Affairs Hospitals and Their Role in Advancing Clinical Research in the United States
Introduction
Veterans Affairs (VA) hospitals form one of the largest integrated healthcare systems in the United States and play a significant role in clinical research. With more than 170 VA medical centers and hundreds of affiliated community-based outpatient clinics, the VA system provides a unique environment for clinical trials, ranging from investigator-initiated studies to large, multicenter industry-sponsored research. The VA Cooperative Studies Program (CSP) has a long history of landmark trials in cardiology, oncology, mental health, and infectious diseases. This article explores the infrastructure, regulatory framework, opportunities, and challenges of conducting clinical trials within the VA system, with insights into its impact on U.S. clinical development.
Background / Regulatory Framework
VA Research Infrastructure
VA hospitals operate a centralized Office of Research and Development (ORD), which governs research policies and provides oversight across the system. Each VA facility has a research office that coordinates trial approvals, compliance, and monitoring, ensuring adherence to both VA policies and federal regulations.
FDA and VA Oversight
Clinical trials conducted at VA hospitals are subject to FDA regulations under 21 CFR Parts 50, 54, 56, and 312, as
Case Example—VA Cooperative Studies Program
The CSP has conducted groundbreaking trials, such as the VA Coronary Artery Bypass Surgery (CASS) trial, which influenced global standards of care. More recent VA oncology trials have focused on immunotherapy and precision medicine, often in collaboration with FDA-regulated sponsors.
Core Clinical Trial Insights
1) Unique Patient Populations
VA hospitals serve a distinct population of veterans, many with complex comorbidities such as cardiovascular disease, PTSD, or chronic pain. This provides opportunities for trials addressing high unmet needs but also requires tailored trial designs and careful ethical considerations.
2) Research Infrastructure and Academic Partnerships
Most VA hospitals are affiliated with major academic medical centers, allowing access to dual faculty investigators, specialized laboratories, and joint IRBs. These partnerships enhance trial capacity and ensure integration with broader U.S. research networks.
3) Funding and Support Mechanisms
VA research is supported by both internal VA funds and external grants from NIH, DoD, and industry sponsors. This diversified funding allows VA sites to participate in investigator-initiated studies as well as pivotal Phase 2 and Phase 3 programs.
4) IRB and Ethical Oversight
VA trials require review by VA-affiliated IRBs or Research and Development Committees, in addition to FDA compliance. VA IRBs emphasize veteran-specific ethical considerations, such as vulnerable populations and equitable access to investigational therapies.
5) Recruitment Strengths and Challenges
VA hospitals provide access to a large, stable patient population, often with long-term medical records. However, recruitment may be limited to veterans, requiring additional outreach for broader trial diversity. FDA encourages inclusion of underrepresented groups beyond VA populations where feasible.
6) Data Systems and Informatics
The VA’s electronic health record system is one of the largest unified medical data repositories in the U.S. This provides unique opportunities for real-world data (RWD) studies and pragmatic trials. FDA has shown interest in RWD integration from VA systems when aligned with regulatory standards.
7) CRO and Sponsor Collaborations
Pharmaceutical sponsors and CROs increasingly partner with VA hospitals for oncology, cardiology, and mental health trials. These collaborations require additional contracting and compliance considerations unique to the VA system.
8) Site Management and Logistics
VA hospitals maintain dedicated research offices but may face bureaucratic hurdles in contracting and approvals. Sponsors must plan for longer start-up timelines compared to private sites, though operational quality is typically high.
9) Regulatory Challenges
FDA inspections at VA sites have highlighted deficiencies such as incomplete documentation, delegation logs, and informed consent gaps. VA hospitals are implementing enhanced training and CAPA programs to address these issues.
10) Future Outlook
With expanding VA partnerships and increasing focus on precision medicine, VA hospitals are expected to play a growing role in oncology, digital health, and decentralized clinical trials. Regulatory harmonization between FDA and VA policies will further streamline research.
Best Practices & Preventive Measures
Sponsors should: (1) engage VA research offices early; (2) prepare for extended contracting and IRB processes; (3) align trial designs with VA patient needs; (4) collaborate with academic affiliates for broader expertise; (5) validate use of VA data systems for regulatory purposes; (6) ensure staff training in FDA and VA-specific requirements; (7) maintain transparent communication with FDA; and (8) implement robust monitoring and CAPA systems for compliance.
Scientific & Regulatory Evidence
References include FDA regulations under 21 CFR Parts 50, 54, 56, and 312, VA ORD research policies, ICH E6(R2) GCP, and case studies from the VA Cooperative Studies Program. These collectively define the regulatory and operational framework for VA clinical research in the U.S.
Special Considerations
VA trials must address ethical challenges related to veterans’ health, including PTSD, mental health, and service-related conditions. Sponsors should design protocols with sensitivity to these issues and include veteran advocacy input where appropriate.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek FDA advice during pre-IND or pre-NDA meetings when including VA hospitals in pivotal trials, especially when using VA data for regulatory submissions. Coordination with both VA and FDA ensures compliance and reduces approval delays.
Case Studies
Case Study 1: Cardiovascular Outcomes Trial
A VA-led cardiovascular trial provided pivotal evidence on hypertension treatment, influencing national guidelines. FDA highlighted the trial as an example of leveraging VA infrastructure for impactful research.
Case Study 2: Oncology Immunotherapy Program
VA hospitals partnered with a pharmaceutical sponsor to conduct an immunotherapy basket trial. The collaboration accelerated patient access and generated high-quality data for FDA submission.
Case Study 3: Mental Health Pragmatic Trial
A VA CSP trial evaluated PTSD therapies using pragmatic trial design and real-world data from the VA health system. FDA acknowledged the innovative design and encouraged similar approaches in mental health research.
FAQs
1) What is the role of VA hospitals in U.S. clinical trials?
VA hospitals conduct investigator-initiated and industry-sponsored trials, leveraging large patient populations and integrated data systems.
2) How are VA trials regulated?
By both FDA regulations under 21 CFR and VA ORD research policies, with oversight from IRBs and Research Committees.
3) What types of trials are common at VA hospitals?
Cardiology, oncology, mental health, and rare disease trials are frequently conducted within the VA system.
4) What challenges do sponsors face in VA trials?
Extended contracting timelines, limited recruitment diversity, and VA-specific compliance requirements.
5) Can VA data be used in FDA submissions?
Yes, if validated and aligned with FDA regulatory requirements, VA electronic health records provide valuable RWD sources.
6) How do CROs collaborate with VA hospitals?
Through vendor qualification, data oversight, and integration of VA-specific processes into broader trial operations.
7) Are VA hospitals involved in decentralized trials?
Yes, VA hospitals increasingly participate in hybrid and decentralized trials, leveraging telehealth and digital health tools.
Conclusion & Call-to-Action
Veterans Affairs hospitals are vital contributors to U.S. clinical research, providing access to unique patient populations and robust data systems. Sponsors can maximize the value of VA collaborations by aligning with FDA and VA requirements, planning for operational complexities, and ensuring strong oversight. Leveraging VA infrastructure not only accelerates innovation but also improves healthcare outcomes for veterans and the wider population.